Cupistem? was approved as adipose tissue-derived mesenchymal stem cell (ASC) product first time in the world by Korean Ministry of Food and Drug Safety (MFDS) as of Jan 2012 and its medical insurance price was granted as of Jan 2014 by Health Insurance Review & Assessment Service (HIRA). The most remarkable feature of this product comes from its sustainability of therapeutic efficacy.

Cupistem? showed that 82% of patients with complex Crohn¡¯s fistula achieved complete healing at week 8 after treatment, 81% out of them sustained response at week 96.